- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
- Latest weekly return ranks in the strongest part of its sector group.
SANN
EBS
Week ended 07 Aug 2026
Weekly Investor Report
Santhera Pharmaceuticals Holding AG · Healthcare · Biotechnology
Latest close
15.84 CHF
11.9%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 1.8% above the Trend Line and sits at 68.3% of its 52-week range. The latest completed week returned 11.9%, after a 4.1% four-week move. The latest news-sentiment score is 50/100.
Setup score
52
out of 100
Latest Close
15.84 CHF
7 Aug 2026
1W Return
11.9%
latest completed week
4W Return
4.1%
short-term follow-through
12W Return
-7.9%
quarterly tape
Trend Breadth
40.4%
21 of 52 weeks active
Volume Ratio
2.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- 2 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
11.9%
Latest completed week; four-week move 4.1%.
Indicator stack
22/36
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 1.8% above the Trend Line and sits at 68.3% of its 52-week range. The latest completed week returned 11.9%, after a 4.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.6x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3212-week average 0.56
12-week confirmation
Trend active8/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership7/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.32Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 4.1% over four weeks, -7.9% over 12 weeks, and 20.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year21
Trend breadth40.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.86Latest activity-pressure read.
Pressure change13.0%Four-week change in activity pressure.
Leadership1.11Latest relative-leadership reading.
RS change166.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 2 relevant articles.
0 positive · 2 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-15.9%Distance below the 52-week high.
13-week volatility5.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+24.0%Week of 13 Feb.
Worst week-9.5%Week of 6 Mar.
Latest week+11.9%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains8
Flat weeks0
Modest losses4
Sharp losses6
Recent vol5.7%13-week weekly-return volatility.
Base vol7.6%52-week weekly-return volatility.
Up/down split30/19Count of positive and negative weeks in the 52-week window.
Average skew5.2% / -6.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCH Healthcare
4-week rank15 / 40
Group average2.0%
Trend breadth52.5%
Trend52.5%active weekly trend signals
MD62.5%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
IndustryCH Biotechnology
4-week rank2 / 11
Group average2.2%
Trend breadth36.4%
Trend36.4%active weekly trend signals
MD36.4%positive activity pressure
RS36.4%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape49/100
Trend, activity pressure, participation, and risk combine to a 49/100 tape read.
Indicator analysis41/100Latest 12-week confirmation: trend 8/12, activity pressure 2/12, relative leadership 7/12.
Activity pressure 0.32; 2 reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 2 relevant articles.
Little Excitement Around Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 15.84 CHF | 11.9% | 15.56 CHF | 11.92 CHF | -0.86 | 1.11 | 634.2K | Off |
| 31 Jul 2026 | 14.16 CHF | -5.0% | 15.52 CHF | 11.88 CHF | -1.10 | -8.39 | 452.8K | Off |
| 24 Jul 2026 | 14.90 CHF | -3.4% | 15.47 CHF | 11.84 CHF | -1.14 | -3.94 | 185.6K | Off |
| 17 Jul 2026 | 15.42 CHF | 1.3% | 15.40 CHF | 11.80 CHF | -1.00 | -0.96 | 423.4K | Off |
| 10 Jul 2026 | 15.22 CHF | 2.8% | 15.30 CHF | 11.75 CHF | -0.99 | -1.66 | 221.4K | On |
| 3 Jul 2026 | 14.80 CHF | -6.4% | 15.19 CHF | 11.71 CHF | -0.94 | -5.55 | 37.9K | On |
| 26 Jun 2026 | 15.82 CHF | -0.8% | 15.11 CHF | 11.67 CHF | -0.72 | 2.79 | 23.4K | On |
| 19 Jun 2026 | 15.94 CHF | 2.2% | 14.99 CHF | 11.62 CHF | -0.71 | 6.79 | 36.9K | On |
| 12 Jun 2026 | 15.60 CHF | -8.5% | 14.86 CHF | 11.57 CHF | -0.66 | 5.32 | 47.8K | On |
| 5 Jun 2026 | 17.04 CHF | 4.5% | 14.69 CHF | 11.52 CHF | -0.30 | 18.07 | 125.7K | On |
| 29 May 2026 | 16.30 CHF | 4.2% | 14.47 CHF | 11.48 CHF | 0.03 | 11.95 | 206.7K | On |
| 22 May 2026 | 15.64 CHF | -9.1% | 14.26 CHF | 11.44 CHF | 0.47 | 8.00 | 364.5K | On |
| 15 May 2026 | 17.20 CHF | 0.5% | 14.08 CHF | 11.39 CHF | 0.85 | 21.63 | 379.8K | On |
| 8 May 2026 | 17.12 CHF | 0.7% | 13.85 CHF | 11.32 CHF | 1.00 | 22.74 | 508.5K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.